Clinical Trials Browser

Phase 1/2 × Melanoma × Infliximab × Clear all

NCT04407247 2025-12-23

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Phase 1/2 Active not recruiting

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Melanoma, Urogenital Neoplasms